Home
Conditions
Virus Diseases

Clinical trial condition

Virus Diseases

Explore clinical trials studying Virus Diseases. Study availability and eligibility vary by location and protocol.

18,951 public trials 1,283 recruiting studies

Refine in advanced search Browse all conditions

Virus Diseases trial results

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

NCT00699231

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Brussels, Belgium

View Trial Details

Completed

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

NCT00698490

Conditions: DNA Virus Infections, Herpes Simplex, Herpesviridae Infections, +7 more
Locations: GSK Clinical Trials Call Center Ghent, Belgium

View Trial Details

Completed

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

NCT00698568

Conditions: DNA Virus Infections, Herpes Simplex, Herpesviridae Infections, +7 more
Locations: GSK Clinical Trials Call Center La Jolla, California, United States

GSK Clinical Trials Call Center Middle Valley, California, United States

GSK Clinical Trials Call Center San Diego, California, United States

GSK Clinical Trials Call Center Denver, Colorado, United States

View all 47 locations

View Trial Details

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

NCT00698555

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Ghent, Belgium

View Trial Details

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

NCT00697931

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Leuven, Belgium

View Trial Details

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

NCT00697775

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Mainz, Germany

View Trial Details

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

NCT00697840

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

NCT00697853

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trial Call Center Brussels, Belgium

View Trial Details

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

NCT00698087

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

NCT00697970

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +8 more
Locations: GSK Clinical Trials Call Center Vienna, Austria

View Trial Details

Virus Diseases

Virus Diseases trial results

Related conditions